Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552036 | 1.00 | ADRB1 (0.44) | ADRB1LMNARAD52SMN1; SMN2ADRB2 | |
| Hydrochloric Acid SCHEMBL6549081 | 0.87 | ADRB1 (0.43) | ADRB1LMNARAD52SMN1; SMN2ADRB2 | |
| SCHEMBL7677813 | 0.80 | ADRB2 (0.54) | ADRB1ADRB2ADRB3 | |
| SCHEMBL7677818 | 0.80 | ADRB2 (0.54) | ADRB1ADRB2ADRB3 | |
| SCHEMBL6550294 | 0.77 | NFE2L2 (0.45) | ADRB1LMNARAD52SMN1; SMN2 | |
| SCHEMBL6549255 | 0.77 | HSF1 (0.46) | SMN1; SMN2 | |
| SCHEMBL6549259 | 0.77 | HSF1 (0.46) | SMN1; SMN2 | |
| SCHEMBL6550288 | 0.77 | NFE2L2 (0.45) | ADRB1LMNARAD52SMN1; SMN2 | |
| SCHEMBL6550745 | 0.75 | SMN1; SMN2 (0.42) | ADRB1SMN1; SMN2ADRB2ADRB3 | |
| SCHEMBL6550742 | 0.75 | SMN1; SMN2 (0.42) | ADRB1SMN1; SMN2ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1115697-B1 | UNSATURATED HYDROXIMIC ACID DERIVATIVES AS PARP INHIBITORS | GENE KUTATO KFT N (HU) | 2004-02-04 | — | — | EP | disclosed |
| US-6500823-B1 | ENERGY DEFICIENCY OF THE CELL CAUSED BY PARP INHIBITION, IN DIABETES COMPLICATIONS, IN OXYGEN DEFICIENT STATUS OF THE HEART AND BRAIN, IN NEURODEGENERATIVE DISEASES, IN THE TREATMENT OF AUTOIMMUNE AND/OR VIRAL DISEASES | N-GENE RESEARCH LABORATORIES, INC. | 2002-12-31 | — | — | US | disclosed |
| EP-1115697-A1 | UNSATURATED HYDROXIMIC ACID DERIVATIVES AS PARP INHIBITORS | N-Gene Kutato KFT. (HU) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000014054-A1 | UNSATURATED HYDROXIMIC ACID DERIVATIVES AS PARP INHIBITORS | N-Gene Kutató Kft. (HU) | 2000-03-16 | — | — | WO | disclosed |